BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sjöwall C, Martinsson K, Cardell K, Ekstedt M, Kechagias S. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. Transl Res. 2015;165:658-666. [PMID: 25445207 DOI: 10.1016/j.trsl.2014.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Enocsson H, Lukic T, Ziegelasch M, Kastbom A. Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time. Transl Res 2021;232:142-9. [PMID: 33582243 DOI: 10.1016/j.trsl.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wei C, Zhu K, Reiser J. Soluble Urokinase Receptor and Liver Disease. Clin Liver Dis (Hoboken) 2019;14:163-6. [PMID: 31879556 DOI: 10.1002/cld.850] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Skovsted TA, Petersen ERB, Fruekilde MB, Pedersen AK, Pielak T, Eugen-Olsen J. Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA. Scand J Clin Lab Invest 2020;80:327-35. [PMID: 32186407 DOI: 10.1080/00365513.2020.1741674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Hamie L, Daoud G, Nemer G, Nammour T, El Chediak A, Uthman IW, Kibbi AG, Eid A, Kurban M. SuPAR, an emerging biomarker in kidney and inflammatory diseases. Postgrad Med J 2018;94:517-24. [PMID: 30177549 DOI: 10.1136/postgradmedj-2018-135839] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
5 Desmedt S, Desmedt V, Delanghe JR, Speeckaert R, Speeckaert MM. The intriguing role of soluble urokinase receptor in inflammatory diseases. Critical Reviews in Clinical Laboratory Sciences 2016;54:117-33. [DOI: 10.1080/10408363.2016.1269310] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
6 Garnæs E, Mortensen C, Hobolth L, Andersen O, Nehlin J, Møller S. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis. PLoS One 2019;14:e0220697. [PMID: 31465463 DOI: 10.1371/journal.pone.0220697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Petersen JEV, Kallemose T, Barton KD, Caspi A, Rasmussen LJH. Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis. BMJ Open 2020;10:e036125. [PMID: 32690515 DOI: 10.1136/bmjopen-2019-036125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Li G, Lin J, Peng Y, Qin K, Wen L, Zhao T, Feng Q. Curcumol may reverse early and advanced liver fibrogenesis through downregulating the uPA/uPAR pathway. Phytother Res 2020;34:1421-35. [PMID: 31989700 DOI: 10.1002/ptr.6616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Tajbakhsh A, Gheibi Hayat SM, Butler AE, Sahebkar A. Effect of soluble cleavage products of important receptors/ligands on efferocytosis: Their role in inflammatory, autoimmune and cardiovascular disease. Ageing Res Rev 2019;50:43-57. [PMID: 30639340 DOI: 10.1016/j.arr.2019.01.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
10 Sevgi DY, Bayraktar B, Gündüz A, Özgüven BY, Togay A, Bulut E, Uzun N, Dökmetaş İ. Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr 2016;128:28-33. [PMID: 26546355 DOI: 10.1007/s00508-015-0886-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
11 Ichihara N, Miyamura M, Maeda D, Fujisaka T, Fujita SI, Morita H, Takeda Y, Ito T, Sohmiya K, Hoshiga M, Ishizaka N. Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation. J Arrhythm 2017;33:469-74. [PMID: 29021852 DOI: 10.1016/j.joa.2017.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
12 Udomsinprasert W, Honsawek S, Jirathanathornnukul N, Chongsrisawat V, Poovorawan Y. Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative biliary atresia. World J Hepatol 2016; 8(33): 1471-1477 [PMID: 27957246 DOI: 10.4254/wjh.v8.i33.1471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Enocsson H, Sjöwall C, Wetterö J. Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus? Clin Chim Acta 2015;444:234-41. [PMID: 25704300 DOI: 10.1016/j.cca.2015.02.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
14 Huang F, Li Y, Xu R, Cheng A, Lv Y, Liu Q. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis. Mediators Inflamm 2020;2020:7850179. [PMID: 32322165 DOI: 10.1155/2020/7850179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zhu L, Chen X, Kong X, Cai YD. Investigation of the roles of trace elements during hepatitis C virus infection using protein-protein interactions and a shortest path algorithm. Biochim Biophys Acta 2016;1860:2756-68. [PMID: 27208424 DOI: 10.1016/j.bbagen.2016.05.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
16 Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, van Vollenhoven RF, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun 2020;106:102340. [PMID: 31629628 DOI: 10.1016/j.jaut.2019.102340] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
17 Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, Cicha M, Rydzewska G. Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity. Pancreatology 2017;17:24-9. [PMID: 27914940 DOI: 10.1016/j.pan.2016.11.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Schultz M, Rasmussen LJH, Høi-Hansen T, Kjøller E, Jensen BN, Lind MN, Ravn L, Kallemose T, Lange T, Køber L, Rasmussen LS, Eugen-Olsen J, Iversen KK. Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy. Dis Markers 2019;2019:3403549. [PMID: 31236143 DOI: 10.1155/2019/3403549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. Front Immunol 2021;12:780641. [PMID: 34925360 DOI: 10.3389/fimmu.2021.780641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wang Y, Wu F, Chen C, Xu L, Lin W, Huang C, Yang Y, Wu S, Qi J, Cao H, Li G, Hong M, Zhu H. Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure. BMC Gastroenterol 2021;21:429. [PMID: 34789156 DOI: 10.1186/s12876-021-02006-x] [Reference Citation Analysis]